INDICATIONS FOR THE TREATMENT OF METASTASIS

BRAIN: For metastasis to the brain, regardless of primary site, refer to the NIA clinical guideline for Central Nervous System (CNS).

BONE: For metastasis to bone, refer to the NIA clinical guideline for bone metastases.

LUNG¹:

- Conventional 2D and 3D-CRT treatment delivery is appropriate for all other secondary malignancies up to ten (10) to fifteen (15) fractions.
  - Treatment beyond ten fractions for 2D-3D-CRT requires physician review and a clinical rationale for additional fractions.

ALL OTHER SITES: For metastasis to any other site other than brain, lung, or bone:

- Conventional 2D and 3D-CRT treatment delivery is appropriate for all other secondary malignancies up to ten (10) fractions.²
  - Treatment beyond ten fractions for 2D-3D-CRT requires physician review and a clinical rationale for additional fractions.

TREATMENT OPTIONS REQUIRING PHYSICIAN REVIEW

- IMRT is not indicated for treatment of metastasis except for limited circumstances in which radiation therapy is indicated and 3D conformal radiation therapy (3D-CRT) techniques cannot adequately deliver the radiation prescription without exceeding normal tissue radiation tolerance, the delivery is anticipated to contribute to potential late toxicity or tumor volume dose.

¹ National Imaging Associates, Inc. (NIA) is a subsidiary of Magellan Healthcare, Inc.

² Metastatic Disease
heterogeneity is such that unacceptable hot or cold spots are created. If IMRT is utilized, techniques to account for respiratory motion should be performed when appropriate.

- Clinical rationale and documentation for performing IMRT rather than 2D or 3D-CRT treatment planning and delivery will need to:
  - Demonstrate how 3D-CRT isodose planning cannot produce a satisfactory treatment plan (as stated above) via the use of patient-specific dose volume histograms and isodose plans. 3D-CRT techniques such as step-and-shoot or field-in-field should be considered for the comparison.
  - Confirm the IMRT requested will be inversely planned (forward plans or 'field-in-field' plans are not considered IMRT).

- **Selective Internal Radiation Therapy (SIRT),** also known as radioembolization with microsphere brachytherapy device (RMBD) and transarterial radioembolization, uses microscopic radioactive spheres to deliver radiation to the tumor site. Treatment is delivered through catheter injection of radioactive Yttrium-90 (90Y) microspheres into the hepatic artery. [For Absolute Contraindication† and Relative Contraindications‡, please see the notes below.] Indications for SIRT include

- Unresectable metastatic liver tumors
- Unresectable metastatic liver tumors from primary colorectal cancer
- Unresectable primary hepatocellular carcinoma
- Unresectable neuroendocrine tumors

†**Note:** Absolute Contraindication
- Fulminant liver failure (absolute)

‡**Note:** Considerations/Relative Contraindications
- The tumor burden should be liver dominant, not necessarily exclusive to the liver
- Patients should also have a performance status that will allow them to benefit from such therapy
- A life expectancy of at least 3 months
- Excessive tumor burden in the liver with greater than 50% to 70% of the parenchyma replaced by tumor
- Total bilirubin greater than 2 mg/dL (in the absence of obstructive cause), which indicates severe liver function impairment. Nonobstructive bilirubin elevations may indicate that liver metastases have caused liver impairment to the degree that risks outweigh benefits for this therapy. In contrast, patients with HCC and elevated bilirubin may be treated with radioembolization if a segmental or subsegmental infusion can be performed
- Prior radiation therapy to the liver or upper abdomen that included a significant volume of the liver

- **Oligometastatic Disease**
  - Stereotactic Body Radiation Therapy (SBRT) is medically necessary for extracranial oligometastatic disease for an individual with One (1) to Five (5) metastatic lesions when the following criteria are met:
- Good performance status: ECOG less than 3 or Karnofsky Scale greater than or equal to 70% and stable systemic disease or reasonable systemic treatment options.

- All other treatment approaches require physician review with presentation of clinical rationale and documentation for the proposed treatment modality and plan.

### POLICY HISTORY

<table>
<thead>
<tr>
<th>Date</th>
<th>Summary</th>
</tr>
</thead>
</table>
| January 2022  | • Added indications for metastasis to lung  
- Under “All Other Sites”, added “lung” to state, “For metastasis to any other site other than brain, lung, or bone”  
- Under SIRT, added notes for absolute contraindication and considerations/relative contraindications  
- Within Oligometastatic Disease, increased the range of metastatic lesions from “One (1) to Four (4)” to “One (1) to Five (5)” |
| February 2021 | Added:  
- Oligometastatic Disease: Stereotactic Body Radiation Therapy (SBRT) is medically necessary for extracranial oligometastatic disease for an individual with One (1) to Four (4) metastatic lesions when the following criteria are met:  
  o Good performance status: ECOG less than 3 or Karnofsky Scale greater than or equal to 70% and stable systemic disease or reasonable systemic treatment options  
- Added References |
| February 2020 | No Changes                                                                                                                                                                                                |
| February 2019 | Added and updated references                                                                                                                                                                            |
REFERENCES


ADDITIONAL RESOURCES


Reviewed / Approved by NIA Clinical Guideline Committee
GENERAL INFORMATION
It is an expectation that all patients receive care/services from a licensed clinician. All appropriate supporting documentation, including recent pertinent office visit notes, laboratory data, and results of any special testing must be provided. If applicable: All prior relevant imaging results and the reason that alternative imaging cannot be performed must be included in the documentation submitted.

Disclaimer: Magellan Healthcare service authorization policies do not constitute medical advice and are not intended to govern or otherwise influence the practice of medicine. These policies are not meant to supplant your normal procedures, evaluation, diagnosis, treatment and/or care plans for your patients. Your professional judgement must be exercised and followed in all respects with regard to the treatment and care of your patients. These policies apply to all Magellan Healthcare subsidiaries including, but not limited to, National Imaging Associates ("Magellan"). The policies constitute only the reimbursement and coverage guidelines of Magellan. Coverage for services varies for individual members in accordance with the terms and conditions of applicable Certificates of Coverage, Summary Plan Descriptions, or contracts with governing regulatory agencies. Magellan reserves the right to review and update the guidelines at its sole discretion. Notice of such changes, if necessary, shall be provided in accordance with the terms and conditions of provider agreements and any applicable laws or regulations.